

GENERAL CONSIDERATIONS

Optimal time to switch from IV to PO antibiotic: **48 to 96 hours** after IV antibiotic initiation

If patient **deteriorate** clinically after the conversion from IV to PO, IV therapy should be reinitiated

If patient fulfill the following criteria, **MAKE** a **switch**!

M	Manifestation of clinical improvement <ul style="list-style-type: none"> Afebrile (36 - 38°C) for 48 hours C-reactive protein (CRP) trending down White cell count (WCC) 4-12* x10⁹/L or trending towards normal range No unexplained tachycardia (HR < 90 bpm) No unexplained hypotension (BP > 90/60 mmHg) and not vasopressor-dependent No tachypnoea (RR < 20 bpm) <p>*Examine the patient's medications for potential cause of increase/sustained high WCC (eg. steroids)</p>				
A	Able to tolerate oral therapy <ul style="list-style-type: none"> Not nil by mouth (NBM) Tolerating oral food or enteral feeding Oral absorption is not compromised by gastrointestinal conditions Good compliance, able to comply to oral medication at home 				
K	Known indication for prolonged course of IV therapy? <table border="1"> <tr> <td data-bbox="386 1258 928 1541"> Conditions <u>suitable</u> for IV to PO switch: <ul style="list-style-type: none"> Pneumonia Skin & soft tissue infections Urinary tract infection Uncomplicated GNR bacteremia Intraabdominal infection without deep seated collections </td><td data-bbox="928 1258 1417 1541"> Conditions <u>not suitable</u> for IV to PO switch: <ul style="list-style-type: none"> ✗ Endocarditis ✗ Central nervous system infections (eg. meningitis, brain abscess) ✗ MSSA bacteremia or fungemia </td></tr> <tr> <td data-bbox="386 1541 928 1751"> Conditions requiring <u>approval from ID physician</u> prior to IV to PO switch: <ul style="list-style-type: none"> Osteomyelitis Septic arthritis Infected implant or prostheses Necrotising soft tissue infection </td><td data-bbox="928 1541 1417 1751"> <ul style="list-style-type: none"> Melioidosis Deep-seated infection (eg. abscesses, empyema) Complicated orbital cellulitis </td></tr> </table>	Conditions <u>suitable</u> for IV to PO switch: <ul style="list-style-type: none"> Pneumonia Skin & soft tissue infections Urinary tract infection Uncomplicated GNR bacteremia Intraabdominal infection without deep seated collections 	Conditions <u>not suitable</u> for IV to PO switch: <ul style="list-style-type: none"> ✗ Endocarditis ✗ Central nervous system infections (eg. meningitis, brain abscess) ✗ MSSA bacteremia or fungemia 	Conditions requiring <u>approval from ID physician</u> prior to IV to PO switch: <ul style="list-style-type: none"> Osteomyelitis Septic arthritis Infected implant or prostheses Necrotising soft tissue infection 	<ul style="list-style-type: none"> Melioidosis Deep-seated infection (eg. abscesses, empyema) Complicated orbital cellulitis
Conditions <u>suitable</u> for IV to PO switch: <ul style="list-style-type: none"> Pneumonia Skin & soft tissue infections Urinary tract infection Uncomplicated GNR bacteremia Intraabdominal infection without deep seated collections 	Conditions <u>not suitable</u> for IV to PO switch: <ul style="list-style-type: none"> ✗ Endocarditis ✗ Central nervous system infections (eg. meningitis, brain abscess) ✗ MSSA bacteremia or fungemia 				
Conditions requiring <u>approval from ID physician</u> prior to IV to PO switch: <ul style="list-style-type: none"> Osteomyelitis Septic arthritis Infected implant or prostheses Necrotising soft tissue infection 	<ul style="list-style-type: none"> Melioidosis Deep-seated infection (eg. abscesses, empyema) Complicated orbital cellulitis 				
E	Equivalent oral antibiotic option? <p>Yes, available (Refer to page 2-3)</p>				

ANTIBIOTICS WITH **EQUIVALENT ORAL OPTIONS** (SEQUENTIAL THERAPY)

Drug	For adults with normal renal function		Bioavailability (BA)	Remarks
	IV dose	Equivalent oral dose		
Amoxicillin/ Clavulanate	1.2 g q8h	625 mg TDS	Amoxicillin: 80% Clavulanate: 30-98%	-
Ampicillin/ Sulbactam	1.5 g q8h 3 g q8h 3 g q6h	375 mg BD 375-750 mg BD 750 mg BD	80%	-
Azithromycin	500 mg q24h	500 mg OD	34-52%	BA compensated by good tissue penetration
Cefuroxime	750 mg q8h 1500 mg q8h	250-500 mg BD 500 mg BD	37-52%	250 mg for sinusitis/pharyngitis, superficial SSTI and uncomplicated UTI
Ciprofloxacin*	400 mg q12h 400 mg q8h	500 mg BD 750 mg BD	50-85%	-
Clindamycin	600 mg q8h 600 mg q6h 900 mg q8h	300 mg QID/ 600 mg TDS 600 mg QID 600 mg QID	~ 90%	300 mg QID for adult < 60 kg
Cloxacillin	500 mg q6h 1000 mg q6h 2000 mg q6h	250 mg QID 500 mg QID 1000 mg QID	~50%	250 mg for mild infections
Fluconazole	200 mg q24h 400 mg q24h 800 mg q24h	200 mg OD 400 mg OD 400 mg BD	> 90%	For opportunistic infections, dose may go up to 1200 mg/day
Levofloxacin*	500 mg q24h 750 mg q24h	500 mg OD 750 mg OD	~ 99%	Hold tube feeds 1H before & 2H after levofloxacin given.
Linezolid	600 mg q12h	600 mg BD	~100%	-
Metronidazole	500 mg q12h 500 mg q8h 750 mg q8h	400 mg BD 400 mg TDS 800 mg TDS	100%	Abstain from alcohol to avoid disulfiram-like reaction
Trimethoprim/ sulfamethoxazole	10-20 mg/kg/day (TMP)	10-20 mg/kg/day (TMP)	90-100%	-

* Space 2 hours before taking fluoroquinolones to avoid concomitant exposure to multivalent cations (Ca, Fe, Al, Mg, Zn) in dairy products, multivitamins and antacids. Cation chelate the drug and prevent absorption.

ANTIBIOTICS FOR **SWITCH/STEP-DOWN THERAPY**

For adults with normal renal function		Bioavailability (BA)
IV dose	Step-down oral dose	
Benzylpenicillin 1-2 mega units q6h 3-4 mega units q4-6h	Phenoxymethylpenicillin 250 mg QID/500 mg BD 500 mg QID or Amoxicillin 500 mg TDS	Phenoxymethylpenicillin: 60-73% Amoxicillin: 80%
Cefazolin 1 g q8h 2 g q8h	Cephalexin 500 mg QID 1000 mg QID	Cephalexin: 90%
Cefepime 2 g q8-12h	Amoxicillin/Clavulanate 625 mg TDS or Sultamicillin 750 mg BD	Amoxicillin: 80% Clavulanate: 30-98% Sultamicillin: 80%
	For definitive <i>Pseudomonas</i> infection: Ciprofloxacin* 500-750 mg BD	Ciprofloxacin: 50-85%
Cefoperazone 1-2 g q12h	Amoxicillin/Clavulanate 625mg TDS or Sultamicillin 375-750 mg BD or Cefuroxime axetil 500 mg BD	Amoxicillin: 80% Clavulanate: 30-98% Sultamicillin: 80% Cefuroxime axetil: 37-52%
	Amoxicillin/Clavulanate 625 mg TDS or Sultamicillin 750 mg BD	Amoxicillin: 80% Clavulanate: 30-98% Sultamicillin: 80%
Ceftazidime 2 g q6-8h	For definitive <i>Pseudomonas</i> infection: Ciprofloxacin* 500-750 mg BD	Ciprofloxacin: 50-85%
	For melioidosis: Trimethoprim/Sulphamethoxazole or Amoxicillin/Clavulanate Refer to H5gB Antibiotic Guideline 2019 for weight-based dosing & duration of antibiotic	TMP/SMZ: 90-100% Amoxicillin: 80% Clavulanate: 30-98%
	Amoxicillin/Clavulanate 625 mg TDS or Cefuroxime axetil 500 mg BD	Amoxicillin: 80% Clavulanate: 30-98% Cefuroxime axetil: 37-52%
Ceftriaxone 1-2 g q24h	Amoxicillin/Clavulanate 625 mg TDS or Cefuroxime axetil 500 mg BD	Amoxicillin: 80% Clavulanate: 30-98% Cefuroxime axetil: 37-52%
Erythromycin Lactobionate 500 mg q6h 1000 mg q6h	Erythromycin Ethylsuccinate 400 mg QID 800 mg QID	Erythromycin: 18-45%
Piperacillin/Tazobactam 4.5 g q6-8h	Amoxicillin/Clavulanate 625 mg TDS or Sultamicillin 750 mg BD	Amoxicillin: 80% Clavulanate: 30-98% Sultamicillin: 80%
	For definitive <i>Pseudomonas</i> infection: Ciprofloxacin* 500-750 mg BD	Ciprofloxacin: 50-85%

* Space 2 hours before taking fluoroquinolones to avoid concomitant exposure to multivalent cations (Ca, Fe, Al, Mg, Zn) in dairy products, multivitamins and antacids. Cation chelate the drug and prevent absorption.

References:

1. Protocol on Antimicrobial Stewardship Program in Healthcare Facilities, MOH latest edition
2. Hospital Sungai Buloh Antibiotic Guideline 2019
3. National Antibiotic Guideline 2019, MOH latest edition

By AMS team & PRIC. Revised 6 November 2020.

Only for internal circulation. For further enquiries, kindly contact ext 4126.

Disclaimer: This guide provides advice of a general nature based on published evidence and expert opinion. This hospital-wide guide has been prepared to promote and facilitate standardization of practice. This guide does not address all the elements of clinical practice and assumes that the individual health-care practitioner to review specific details of each patient and professionally assess the applicability of the guide to that clinical situation

